AEON Biopharma reported a net loss of $1.16 million for the second quarter of 2026, primarily reflecting ongoing clinical development costs for its Botox biosimilar candidate, ABP-450. While the company ended the quarter with a limited cash balance, a subsequent $15.3 million public offering in July has significantly bolstered the balance sheet to support operations through early next year.
Key Highlights
- Research and development expenses totaled $2.9 million for the quarter, driven by the advancement of the ABP-450 analytical similarity program.
- Pro-forma cash runway now extends into the first quarter of 2027 following the completion of an underwritten public offering that yielded $13.6 million in net upfront proceeds.
- Management confirmed the receipt of positive FDA feedback from a Biosimilar Biological Product Development Type 2a meeting, with a follow-up Type 2b meeting scheduled for the second half of 2026.